CollPlant Biotechnologies Ltd. – NASDAQ:CLGN
CollPlant Biotechnologies Ltd. stock price today
$2.46
-1.10
-31.09%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
CollPlant Biotechnologies Ltd. stock price monthly change
-28.60%
month
CollPlant Biotechnologies Ltd. stock price quarterly change
-28.60%
quarter
CollPlant Biotechnologies Ltd. stock price yearly change
-45.50%
year
CollPlant Biotechnologies Ltd. key metrics
Market Cap | 40.20M |
Enterprise value | 51.91M |
P/E | -4.99 |
EV/Sales | 51.60 |
EV/EBITDA | -3.74 |
Price/Sales | 81.33 |
Price/Book | 2.28 |
PEG ratio | -0.04 |
EPS | -0.65 |
Revenue | 10.62M |
EBITDA | -7.22M |
Income | -7.49M |
Revenue Q/Q | -77.36% |
Revenue Y/Y | 1495.19% |
Profit margin | -1469.09% |
Oper. margin | -1472.17% |
Gross margin | 12.72% |
EBIT margin | -1472.17% |
EBITDA margin | -67.96% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCollPlant Biotechnologies Ltd. stock price history
CollPlant Biotechnologies Ltd. stock forecast
CollPlant Biotechnologies Ltd. financial statements
Average Price Target
$12.5
Potential upside: 408.13%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 10.18M | 5.76M | 56.58% |
|---|---|---|---|
| Sep 2023 | 43K | -4.37M | -10179.07% |
| Dec 2023 | 299K | -4.68M | -1568.23% |
| Mar 2024 | 98K | -4.19M | -4280.61% |
| Jun 2023 | 41569000 | 5.53M | 13.3% |
|---|---|---|---|
| Sep 2023 | 37558000 | 5.16M | 13.74% |
| Dec 2023 | 34126000 | 5.78M | 16.95% |
| Mar 2024 | 30293000 | 5.84M | 19.3% |
| Jun 2023 | -3.74M | -396K | 89K |
|---|---|---|---|
| Sep 2023 | 6.77M | -243K | 216K |
| Dec 2023 | -2.26M | -356.15K | -3.94K |
| Mar 2024 | -3.25M | -82K | 9K |
CollPlant Biotechnologies Ltd. alternative data
| Aug 2023 | 73 |
|---|---|
| Sep 2023 | 73 |
| Oct 2023 | 73 |
| Nov 2023 | 73 |
| Dec 2023 | 73 |
| Jan 2024 | 73 |
| Feb 2024 | 73 |
| Mar 2024 | 73 |
| Apr 2024 | 73 |
| May 2024 | 75 |
| Jun 2024 | 75 |
| Jul 2024 | 75 |
CollPlant Biotechnologies Ltd. other data
13.79%
-0.43%
of CLGN is owned by hedge funds
1.52M
-55.35K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 29 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 4 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 29 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 24 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Yehiel Tal (1952) Chief Executive Officer | $595,000 |
Mr. Eran Rotem CPA (1968) Deputy Chief Executive Officer & Chief Financial Officer | $451,000 |
Dr. Ilana Belzer (1960) Chief Operations Officer | $270,000 |
-
What's the price of CollPlant Biotechnologies Ltd. stock today?
One share of CollPlant Biotechnologies Ltd. stock can currently be purchased for approximately $2.46.
-
When is CollPlant Biotechnologies Ltd.'s next earnings date?
Unfortunately, CollPlant Biotechnologies Ltd.'s (CLGN) next earnings date is currently unknown.
-
Does CollPlant Biotechnologies Ltd. pay dividends?
No, CollPlant Biotechnologies Ltd. does not pay dividends.
-
How much money does CollPlant Biotechnologies Ltd. make?
CollPlant Biotechnologies Ltd. has a market capitalization of 40.20M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3565.22% to 10.96M US dollars.
-
What is CollPlant Biotechnologies Ltd.'s stock symbol?
CollPlant Biotechnologies Ltd. is traded on the NASDAQ under the ticker symbol "CLGN".
-
What is CollPlant Biotechnologies Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CollPlant Biotechnologies Ltd.?
Shares of CollPlant Biotechnologies Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are CollPlant Biotechnologies Ltd.'s key executives?
CollPlant Biotechnologies Ltd.'s management team includes the following people:
- Mr. Yehiel Tal Chief Executive Officer(age: 73, pay: $595,000)
- Mr. Eran Rotem CPA Deputy Chief Executive Officer & Chief Financial Officer(age: 57, pay: $451,000)
- Dr. Ilana Belzer Chief Operations Officer(age: 65, pay: $270,000)
-
How many employees does CollPlant Biotechnologies Ltd. have?
As Jul 2024, CollPlant Biotechnologies Ltd. employs 75 workers, which is 3% more then previous quarter.
-
When CollPlant Biotechnologies Ltd. went public?
CollPlant Biotechnologies Ltd. is publicly traded company for more then 7 years since IPO on 31 Jan 2018.
-
What is CollPlant Biotechnologies Ltd.'s official website?
The official website for CollPlant Biotechnologies Ltd. is collplant.com.
-
How can i contact CollPlant Biotechnologies Ltd.?
CollPlant Biotechnologies Ltd. can be reached via phone at +972 73 232 5600.
-
What is CollPlant Biotechnologies Ltd. stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for CollPlant Biotechnologies Ltd. in the last 12 months, the avarage price target is $12.5. The average price target represents a 408.13% change from the last price of $2.46.
CollPlant Biotechnologies Ltd. company profile:
CollPlant Biotechnologies Ltd.
collplant.comExchange:
NASDAQ
Full time employees:
75
Industry:
Biotechnology
Sector:
Healthcare
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Weizmann Science Park
Rehovot, 7670104
Rehovot, 7670104
CIK: 0001631487
ISIN: IL0004960188
CUSIP: 19516R107
